Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Ovarian cancer is where there is uncontrolled growth of abnormal cells in the ovary, leading to the development of tumors. There are several kinds of ovarian cancer: epithelial cancer, primary peritoneal cancer and fallopian tube cancer.
Treatment ranges from surgery to chemotherapy, with common chemotherapy drugs carboplatin and paclitaxel being most often used. However, there are many limitations to chemotherapy in advanced cases, this review paper published in Nanomedicine discusses how nano drugs can be used to overcome these limitations.
Abstract: Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review.
